Inheritest Core



We're making it easy to empower patients with information regarding their carrier status for cystic fibrosis (CF), spinal muscular atrophy (SMA), and fragile X syndrome with the Inheritest Core carrier screen.

ACOG's most recent recommendations state that carrier screening for SMA and CF "should be offered to all women who are considering pregnancy or are currently pregnant."¹

Why Inheritest Core?


• All-in-one.

CF, SMA and fragile X syndrome are now available together with one lab report, and one bill for these three disorders.*

- Determine if the baby is affected.
 For pregnancies at risk, we also offer prenatal testing to determine whether the baby has the parental mutations, saving patients time and additional testing.
- Enhanced insight for CF risk.

As CF is a common hereditary disorder in the US, we offer an additional safeguard. If a patient screens positive for CF, we can offer her partner full gene-specific sequencing, reporting all disease-causing variants and variants of uncertain significance.

*CF, SMA and fragile X syndrome are still available to order individually



Learn more by visiting www.integratedgenetics.com or calling 800-848-4436.



© 2017 Laboratory Corporation of America® Holdings. All rights reserved. rep-1080-v2-0617



Why focus on CF, SMA, and fragile X syndrome?

Not only are CF, SMA, and fragile X syndrome some of the most common genetic disorders, but they're also some of the most severe.

Disorder	Carrier frequency	Details
Cystic fibrosis	1 in 25 (Caucasian) ²	A common severe hereditary disorder in the US
Spinal muscular atrophy	1 in 54 (all ethnicities) ³	A common inherited cause of early childhood death
Fragile X syndrome	Approximately 1 in 259 females (all ethnicities) ⁴	A leading inherited cause of intellectual and developmental disabilities

Why Integrated Genetics?

Inheritest Core is available through Integrated Genetics, which delivers a continuum of care for your patients from carrier screening to noninvasive prenatal testing (NIPT, also known as cfDNA testing) to diagnostic testing.

We provide the scientific expertise you need, and the customer experience patients want.

- Rapid results: Samples have a typical turnaround time of 5-8 calendar days after a test arrives at our lab.
- Extensive managed care contracts: Helps patients maximize their benefits.
- **Convenient blood draws**: We have a nationwide network of patient service centers, allowing for convenient access to sample collection. Visit www.LabCorp.com to find your nearest location.
- **Genetic counseling**: Patients with a positive test result may be offered counseling, and Integrated Genetics offers the largest national commercial network of genetic counselors to help inform and support patients.

Test code	Test description	Specimen requirements
451964	Inheritest Core panel (CFplus, SMA,	10 mL whole blood, ACD-A (yellow
	fragile X syndrome [females only])	top) or EDTA (lavender top) tube

- 1. Carrier Screening for Genetic Conditions. Committee Opinion No. 691. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;129:e41-55
- 2. Update on Carrier Screening for Cystic Fibrosis. ACOG Committee Opinion Number 486. American College of Obstetrics and Gynecologists. *Obstet Gynecol* 2011; 117:1028-1031
- 3. Sugarman EA, et al. Pan-ethnic Carrier Screening and Prenatal Diagnosis for Spinal Muscular Atrophy: Clinical Laboratory Analysis of >72,400 specimens. *Eur J Hum Genet* 2012; 20:27-32
- 4. Dombrowski C, et al. Premutation and intermediate-size FMR1 alleles in 10572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. *Hum Mol Genet*. 2002 11(4):371-8



© 2017 Laboratory Corporation of America® Holdings. All rights reserved. rep-1080-v2-0617